Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Fig 2
EZH2 inhibition modulates expression of synovial sarcoma-related genes.
(A) Quantitative real-time PCR (qPCR) analysis of the indicated cell lines treated with tazemetostat at the indicated doses for 2, 4 or 7 days. Data are normalized to GAPDH expression relative to the vehicle control. Data are represented as mean values ± SEM (n = 3). (B) qPCR analysis of HS-SY-II or Fuji xenograft samples treated with tazemetostat at the indicated doses, twice daily, for 7 days. Tumors were harvested 3 hours after the last dose on day 7. Data are normalized to GAPDH expression or 18s rRNA expression relative to the vehicle control and represents the average of 5 independent animals per group ± SEM. For this whole figure: * P< 0.05, ** P<0.01, *** P<0.001, **** P<0.0001, vs. vehicle control, one-way analysis of variance followed by the Dunnett’s multiple comparisons test.